Kyowa Kirin, Inc.
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1949-01-01
- Employees
- 7.1K
- Market Cap
- $12B
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)
- Conditions
- X-linked Hypophosphatemia
- Interventions
- Biological: burosumab
- First Posted Date
- 2014-06-13
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02163577
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇫🇷Bicetre Hospital, Le Kremlin- Bicetre, France
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 372
- Registration Number
- NCT01728805
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
- Conditions
- Adult T-cell Leukemia-Lymphoma
- Interventions
- First Posted Date
- 2012-06-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT01626664
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇫🇷Hospital Necker, Paris, France
A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Registration Number
- NCT00955045
- Locations
- 🇺🇸
48 Centers in the US and 4 in Canada, Princeton, New Jersey, United States
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT00575562
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa
- Conditions
- Parkinson's Disease
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 325
- Registration Number
- NCT00456794
- Locations
- 🇺🇸
Contact Kyowa Pharmaceutical, Inc., Princeton, New Jersey, United States
12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/Carbidopa
- Conditions
- Parkinson's Disease
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT00456586
- Locations
- 🇺🇸
Contact Kyowa Pharmacuetical Inc., Princeton, New Jersey, United States
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaMyelodysplastic SyndromesAcute Myelogenous LeukemiaChronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT00346632
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Contact Kyowa, Princeton, New Jersey, United States
🇺🇸M.D. Anderson Cancer Center, Houston, Texas, United States
Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome
- Conditions
- Sleep DisorderRestless Legs Syndrome
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT00199446
- Locations
- 🇺🇸
Kyowa Pharmaceutical Inc., Princeton, New Jersey, United States
An Extension of Istradefylline in North American Parkinson's Disease Patients Who Have Completed Study 6002-INT-001
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 504
- Registration Number
- NCT00199381
- Locations
- 🇺🇸
Kyowa Pharmaceutical Inc., Princeton, New Jersey, United States